Longitudinal [
ApoE-deficiency
Brain stem
Cerebral glucose metabolism
Proton magnetic resonance spectroscopy
[18F]FDG-PET/CT imaging
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
07 Oct 2020
07 Oct 2020
Historique:
received:
29
07
2020
accepted:
24
09
2020
entrez:
8
10
2020
pubmed:
9
10
2020
medline:
9
10
2020
Statut:
epublish
Résumé
Strong line of evidence suggests that the increased risk to develop AD may at least be partly mediated by cholesterol metabolism. A key regulator of cholesterol transport is the Apolipoprotein E4 (ApoE4), which plays a fundamental role in neuronal maintenance and repair. Impaired function of ApoE4 may contribute to altered cerebral metabolism leading to higher susceptibility to neurodegeneration. To determine a possible link between ApoE function and alterations in AD in the brain of Apolipoprotein E-deficient mice (ApoE-/-) in a longitudinal manner metabolic and neurochemical parameters were analyzed. Cortical metabolism was measured by 2-deoxy-2-[ By using [ In summary, this longitudinal in vivo study shows for the first time that ApoE-/- mice depict cerebral hypometabolism without neurochemical alterations.
Sections du résumé
BACKGROUND
BACKGROUND
Strong line of evidence suggests that the increased risk to develop AD may at least be partly mediated by cholesterol metabolism. A key regulator of cholesterol transport is the Apolipoprotein E4 (ApoE4), which plays a fundamental role in neuronal maintenance and repair. Impaired function of ApoE4 may contribute to altered cerebral metabolism leading to higher susceptibility to neurodegeneration.
METHODS
METHODS
To determine a possible link between ApoE function and alterations in AD in the brain of Apolipoprotein E-deficient mice (ApoE-/-) in a longitudinal manner metabolic and neurochemical parameters were analyzed. Cortical metabolism was measured by 2-deoxy-2-[
RESULTS
RESULTS
By using [
CONCLUSION
CONCLUSIONS
In summary, this longitudinal in vivo study shows for the first time that ApoE-/- mice depict cerebral hypometabolism without neurochemical alterations.
Identifiants
pubmed: 33029684
doi: 10.1186/s13550-020-00711-4
pii: 10.1186/s13550-020-00711-4
pmc: PMC7541807
doi:
Types de publication
Journal Article
Langues
eng
Pagination
119Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : KU 3280/1-2
Références
J Neurosci. 2015 Nov 25;35(47):15716-30
pubmed: 26609163
J Cereb Blood Flow Metab. 2015 Jan;35(1):86-94
pubmed: 25335802
Ann Neurol. 1994 May;35(5):546-51
pubmed: 8179300
Eur Neuropsychopharmacol. 2014 Oct;24(10):1659-75
pubmed: 25130303
Neurology. 2006 Feb 28;66(4):540-4
pubmed: 16505309
J Nucl Med. 2011 May;52(5):800-7
pubmed: 21498533
Ann Nucl Med. 2003 Apr;17(2):79-89
pubmed: 12790355
Aging (Albany NY). 2016 Nov 29;8(11):2777-2789
pubmed: 27902456
PLoS One. 2013 Jul 10;8(7):e68778
pubmed: 23874758
Neuroimage. 2012 May 1;60(4):2316-22
pubmed: 22348880
Psychiatry Res. 2008 Nov 30;164(2):143-53
pubmed: 18930634
Neurobiol Aging. 2012 Sep;33(9):1995-2005
pubmed: 22079157
Neuroimage. 2008 Apr 15;40(3):1214-21
pubmed: 18280754
J Cereb Blood Flow Metab. 2017 Aug;37(8):2870-2882
pubmed: 27834284
J Neuroimaging. 2012 Jan;22(1):21-7
pubmed: 21332873
Neurobiol Dis. 2005 Feb;18(1):32-9
pubmed: 15649694
J Lipid Res. 2017 Dec;58(12):2239-2254
pubmed: 28298292
J Nucl Med. 2016 Feb;57(2):221-5
pubmed: 26609179
Science. 2001 Nov 9;294(5545):1354-7
pubmed: 11701931
Ann Nucl Med. 2008 Apr;22(3):191-200
pubmed: 18498034
Dev Neurosci. 1998;20(4-5):271-6
pubmed: 9778562
Medicine (Baltimore). 2017 Dec;96(48):e9042
pubmed: 29310421
Ann Med. 1995 Dec;27(6):663-70
pubmed: 8652146
Clin Nucl Med. 2019 Jan;44(1):e1-e5
pubmed: 30325816
J Nucl Med. 2017 Dec;58(12):1984-1990
pubmed: 28705919
J Exp Med. 2017 Mar 6;214(3):699-717
pubmed: 28213512
Front Biosci. 2001 Mar 01;6:D515-25
pubmed: 11229870
Dement Geriatr Cogn Disord. 2005;20(2-3):178-83
pubmed: 16024934
J Neural Transm (Vienna). 1998;105(8-9):821-37
pubmed: 9869321
Science. 1993 Aug 13;261(5123):921-3
pubmed: 8346443
Psychiatry Res. 2014 Jan 30;221(1):78-85
pubmed: 24262800
Prog Neurobiol. 2007 Feb;81(2):89-131
pubmed: 17275978
J Nucl Med. 2016 Jun;57(6):954-60
pubmed: 26912428
Neurosci Lett. 2004 Oct 14;369(2):87-92
pubmed: 15450674
Behav Brain Res. 2012 Nov 1;235(1):1-6
pubmed: 22828014
Physiol Rev. 2014 Oct;94(4):1077-98
pubmed: 25287860
Front Aging Neurosci. 2019 Jan 08;10:425
pubmed: 30670962
J Neurosci. 2018 Jul 25;38(30):6665-6681
pubmed: 29967007
Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11906-10
pubmed: 16091461
J Neurosci. 2014 Oct 15;34(42):13963-75
pubmed: 25319693
Biol Psychiatry. 2008 Mar 15;63(6):609-18
pubmed: 17720148
Magn Reson Med. 1999 Apr;41(4):649-56
pubmed: 10332839
Trends Immunol. 2016 Sep;37(9):608-620
pubmed: 27443914
Arch Neurol. 2009 May;66(5):632-7
pubmed: 19433663
Mol Imaging. 2016 Feb 11;15:
pubmed: 27030402
J Alzheimers Dis Rep. 2017 Nov 16;1(1):169-180
pubmed: 30480236
Int J Biomed Imaging. 2016;2016:7462014
pubmed: 26880871
Neurobiol Aging. 2008 Sep;29(9):1423-33
pubmed: 17434239
Neuroscientist. 2007 Feb;13(1):38-48
pubmed: 17229974
Neurology. 2013 Jan 22;80(4):359-65
pubmed: 23255822
Prog Lipid Res. 2011 Jan;50(1):62-74
pubmed: 20854843
Proc Natl Acad Sci U S A. 2018 Feb 20;115(8):E1896-E1905
pubmed: 29437957
Free Radic Biol Med. 2004 May 1;36(9):1155-62
pubmed: 15082069
Lancet Neurol. 2010 Jan;9(1):119-28
pubmed: 20083042
PLoS One. 2013 Nov 11;8(11):e79977
pubmed: 24244584
Pharmacogenomics. 2007 Aug;8(8):959-69
pubmed: 17716229
Neuroscience. 1999;91(1):401-3
pubmed: 10336088
Neurosci Lett. 1995 Oct 13;199(1):5-8
pubmed: 8584225
Neuroimage Clin. 2017 Jun 09;15:581-586
pubmed: 28652970
Cell Mol Life Sci. 2003 Jun;60(6):1158-71
pubmed: 12861382
Arterioscler Thromb Vasc Biol. 2016 Jul;36(7):1305-15
pubmed: 27174096
Hum Mol Genet. 1994 Apr;3(4):569-74
pubmed: 8069300
FEBS Lett. 2005 Nov 21;579(28):6411-6
pubmed: 16288750